Silo pharma selects veloxity labs for bioanalytical ind-enabling study for our novel intranasal ptsd therapy, spc-15

Sarasota, fl, may 14, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged veloxity labs, llc for bioanalysis supporting the ongoing investigational new drug (ind)-enabling glp (good laboratory practice)-compliant toxicology and toxicokinetics study of its lead asset, spc-15, an intranasal prophylactic treatment for post-traumatic stress disorder (ptsd). “we look forward to working with veloxity labs for glp sample analysis in our current safety study of spc-15,” said eric weisblum, ceo of silo.
SILO Ratings Summary
SILO Quant Ranking